Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALT-801 With Cisplatin in Metastatic Melanoma
NCT01029873Phase 2Terminated
- Sponsor
- Altor BioScience Corporation
- Start
- Feb 2010
- Primary completion
- Nov 2011
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of pemvidutide in melanoma, sponsored by Altor BioScience Corporation. Started Feb 2010; status: terminated.
02
Drugs
pemvidutide
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01029873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01029873.